Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study

被引：0
|
作者：
Israelyan, E. R. [1 ]
Tryakin, A. [2 ]
Rumyantsev, A. [1 ]
Fedyanin, M. [3 ]
Tyulyandina, A. [1 ]
Klimov, A. [4 ]
Matveev, V. [5 ]
Volkova, M. I. [6 ]
Paychadze, A. [7 ]
Bychkov, Y. [8 ,9 ]
Yunaev, G. [10 ]
Tsareva, A. [1 ]
Tikhomirova, T. [1 ]
Zorinova, A. [1 ]
Tjulandin, S. [11 ]
机构：
[1] Natl Med Res Ctr Oncol, Chemotherapy Dept 4, Moscow, Russia
[2] Natl Med Res Ctr Oncol, Clin Pharmacol & Chemotherapy Dept, Moscow, Russia
[3] Moscow Dept Hlth, Chemotherapy Dept, Moscow Multidisciplinary Clin Ctr Kommunarka, Moscow, Russia
[4] Natl Med Res Ctr Oncol, Oncourol Dept, Moscow, Russia
[5] NN Blokhin Natl Med Res Ctr Oncol, Oncourol Dept, Moscow, Russia
[6] City Clin Hosp, Moscow Healthcare Dept, Genitourinary Oncol Dept, Oncol Ctr 1, Moscow, Russia
[7] PA Hertsen Moscow Oncol Res Inst, Chemotherapy Dept, Moscow, Russia
[8] Russian Ctr Rentgenoradiol, Chemotherapy Dept, Moscow, Russia
[9] Moscow Res Inst Diagnost & Surg, Chemotherapy Dept, Moscow, Russia
[10] Natl Med Res Ctr Oncol, Intens Care Dept, Moscow, Russia
[11] Natl Med Res Ctr Oncol, Chemotherapy Dept 22, Moscow, Russia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.770
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
707P
引用
收藏
页码：S543 / S543
页数：1
相关论文
共 50 条
  • [21] Dose-dense BEP (ddBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): Safety results of phase II trial
    Tryakin, Alexey
    Fedyanin, Mikhail
    Sergeev, Urii
    Bulanov, Anatoly
    Ahmedov, Bahrom
    Zakharova, Tatiana
    Mitin, Andrey
    Feinstein, Igor
    Garin, August
    Tjuiandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Impact of extrascrotal symptoms on treatment outcome in patients with nonseminomatous germ cell tumor with intermediate or poor prognosis
    Yamada, Shigeyuki
    Saito, Hideo
    Mitsuzuka, Koji
    Ito, Akihiro
    Arai, Yoichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [23] Paclitaxel plus BEP (T-BEP) Regimen as Induction Chemotherapy in Poor Prognosis Patients With Nonseminomatous Germ Cell Tumors: A Phase II Study
    Tryakin, A.
    Fedyanin, M.
    Kanagavel, D.
    Fainstein, I.
    Sergeev, J.
    Polockij, B.
    Matveev, V.
    Zakharova, T.
    Garin, A.
    Tjulandin, S.
    UROLOGY, 2011, 78 (03) : 620 - 625
  • [24] Prognostic significance of elevated serum tumor markers (STM) after the first cycle of chemotherapy in patients with intermediate and poor risk non seminomatous testicular germ cell tumors (NSGCT)
    Batra, A.
    Nayak, B.
    Singh, P.
    Sahoo, R. K.
    Kunhiparambath, H.
    Kaushal, S.
    Seth, A.
    Varshney, A. N.
    Raj, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S778 - S778
  • [25] Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors
    Fizazi, K
    Culine, S
    Kramar, A
    Amato, RJ
    Bouzy, J
    Chen, I
    Droz, JP
    Logothetis, CJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (19) : 3868 - 3876
  • [26] Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumours (NSGCT): Final results of phase II trial
    Tryakin
    Fedyanin, M.
    Segeev, Y.
    Bulanov, A.
    Matveev, V. B.
    Volkova, M.
    Klimov, A.
    Fainstein, I.
    Akhmedov, B.
    Menshikova, S.
    Zakharova, T.
    Garin, A. M.
    Chekini, D.
    Chekini, A.
    Sekhina, O.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts).
    Feldman, Darren Richard
    Voss, Martin Henner
    Jia, Xiaoyu
    Van Alstine, Lindsay Joy
    Patil, Sujata
    Fischer, Patricia
    Sheinfeld, Joel
    Bosl, George J.
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Prognostic significance of primary tumor morphology on progression-free survival (PFS) in patients (pts) with metastatic nonseminomatous germ cell tumors (NSGCT)
    Fedianin, M.
    Tryakin, A.
    Zakharova, T.
    Fainstein, I.
    Figurin, K.
    Polckii, B.
    Sergeev, Y.
    Garin, A.
    Tjulandin, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 308 - 308
  • [29] Salvage chemotherapy for relapsed germ cell tumors: A phase II trial of gemcitabine, paclitaxel, ifosfamide, and cisplatin (Gem-TIP)
    Wheater, Matthew James
    Huddart, Robert Anthony
    White, Jeff D.
    Rustin, Gordon J. S.
    Hennig, Ivo M.
    Cozens, Kelly
    Bowers, Megan
    Cross, Nadia
    Mead, Graham
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Prognostic significance of early predicted time to normalization (TTN) of tumor markers in advanced nonseminomatous germ cell tumors (NSGCT): validation study
    Tryakin, A.
    Tjulandin, S.
    Titov, D.
    Zakharova, T.
    Figurin, K.
    Mitin, A.
    Fainstein, I.
    Garin, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 250 - 250
12345